« Previous
Next »
The Breast
Volume 19, Issue 2
, Pages
92-96
, April 2010
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy
To access this article, please choose from the options below
☆ This study was conducted as a trial of the Mayo Cancer Center Research Consortium in part by Public Health Service grants CA-35431, CA-35195, and CA-52352. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health.
☆☆ Additional participating institutions include: Carle Cancer Center CCOP, Urbana, IL 61801 (Kendrith M. Rowland, Jr.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld).
PII: S0960-9776(09)00173-8
doi: 10.1016/j.breast.2009.12.001
© 2009 Elsevier Ltd. All rights reserved.
« Previous
Next »
The Breast
Volume 19, Issue 2
, Pages
92-96
, April 2010
